Related Experiment Videos

Hepatic resection for metastatic tumors from noncolorectal carcinoma

Y Takada1, M Otsuka, K Seino

  • 1Department of Surgery, Institute of Clinical Medicine, Tsukuba University, Ten-nodai 1-1-1, Tsukuba, Ibaraki 305-8575, Japan.

Abstract

Insights

Hepatic resection for noncolorectal cancer metastases shows potential benefit in select cases. Metachronous gastric cancer metastases had better survival outcomes than synchronous ones, while pancreatobiliary cancers showed limited benefit.

Area of Science:

  • Hepatobiliary Surgery
  • Surgical Oncology
  • Gastrointestinal Oncology

Background:

  • The efficacy of liver resection for noncolorectal cancer metastases remains unclear.
  • This study evaluates outcomes from a single institution's experience.

Purpose of the Study:

  • To clarify the role of hepatic resection in treating liver metastases from noncolorectal carcinomas.
  • To analyze survival data based on primary cancer type and disease presentation (synchronous vs. metachronous).

Main Methods:

  • A retrospective review of 14 patients who underwent curative liver resection for noncolorectal metastases between 1987 and 1999.
  • Analysis of patient records to determine primary cancer type, disease timing, and survival outcomes.

Main Results:

  • Resections were performed for gastric (n=8), pancreatic (n=2), bile duct, Vater's papilla, kidney, and breast cancers.
  • Gastric cancer metastases: 2 metachronous survivors (26, 53 months); all 5 synchronous patients died within 29 months.
  • Pancreatobiliary cancers: all 4 patients died within 2 years. Renal cell and breast cancer cases showed long-term survival.

Conclusions:

  • Hepatic resection for metachronous gastric cancer liver metastases may offer survival benefits.
  • Limited benefit observed for liver metastases from pancreatobiliary cancers following resection.

Related Concept Videos